This article is more than 5 years old. Information may no longer be current.

Sight Again project receives €18.5 million in funding

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GenSight Biologics, Pixium Vision and Fondation Voir et Entendre announced that the Sight Again project will receive €18.5 million in funding over the next 5 years as part of the Investment for the Future, according to a press release.

Sight Again is a public-private research and development project to restore vision to legally blind patients with different stages of retinitis pigmentosa. Sight Again is focused on the development of two products: an optogenetic gene therapy product (GenSight Biologics) and a vision restoration system with Prima, a retinal implant (Pixium Vision), the release said.

Fondation Voir et Entendre is a scientific cooperation aimed at increasing the scientific and medical potential of the Institut de la Vision to meet the sensory challenges of hearing and vision impairments, the release said.

The €18.5 million will distributed among GenSight Biologics, Pixium Vision and Fondation Voir et Entendre.